20-30% of our population have non-alcoholic fatty liver disease (NAFLD) and have abnormal LFTs. We will present the new NAFLD pathway and outline which patients need further investigations. There are new guidelines in the management of Hepatitis B, which will be presented, and we will discuss our proposed plans for the monitoring and treatment of Hep B patients in the future.
Speaker(s)
Rob Palmer and Dr Iain Ewing